Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Orphaning Biotech? The Impact of Biosimilars on Biotech Investment

This article was originally published in RPM Report

Executive Summary

An abbreviated follow-on biologics pathway is inevitable, despite the fact that Congress failed to pass legislation in 2007. Will a FOBs pathway adversely impact money flowing into the biotech industry? Unlikely. The impact of the 1983 Orphan Drug Act may be a good model to consider.

You may also be interested in...

FDA's Balancing Act: Early Hints at a Biosimilars

FDA opened the regulatory phase of the biosimilar debate by hearing from industry and other stakeholders about what an approval system should look like. But this information-gathering session wasn’t all one-sided: FDA officials offered some hints of what they are thinking too. And while there are some significant areas of disagreement—and outlier positions—there was also quite a bit of common ground.

Orphan Drug Standards: Systematic Flexibility

The National Organization for Rare Disorders wants FDA to be a bit more rigorous in communicating its regulatory standards. The agency has always been flexible in determining how much evidence of safety and efficacy is necessary when it comes to orphan drugs; sponsors, investors and patients would benefit if that is more clearly spelled out.

Preparing for the Arrival of Follow-On Biologics

A handful of follow-on biologics are already offered in European and American markets, but have yet to cause signifi cant brand erosion. Yet despite ongoing regulatory and commercial uncertainties, Big Pharma and small molecule generics companies have been making strategic moves to enter into the biosimilar arena. This article, written by experts from the Campbell Alliance, examines the current movement toward an abbreviated approval pathway for follow-on biologics in the US and assesses the potential impact on current biotechnology products. In addition, the article provides some insight into what commercial and reimbursement decision makers for biotechnology companies should be doing to prepare for the arrival of biosimilars.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts